Clinical trials: Anlotinib
Sarcoma,Soft Tissue, Extremity
Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）
To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination…
- Conditions
- Sarcoma,Soft Tissue, Extremity, Trunk, Anlotinib
- Trial name
- SPARE-01 (NCT05167994)
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Malignant Neoplasms of Digestive Organs
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.
- Trial name
- NCT05934331
- Testing
- LM-302, Toripalimab, Capecitabine
- Where
- China
- Volunteers
- 632 people
- Sponsor
- LaNova Medicines Zhejiang Co., Ltd.
Malignant Glioma
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
A Phase II Study of Hypofractionated Stereotactic Radiotherapy (HSRT) With Anlotinib in Patients With Recurrent High-Grade Glioma. The primary endpoint is overall survival after radiotherapy.
- Trial name
- NCT04197492
- Testing
- Hypofractionated Stereotactic Radiotherapy, Anlotinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Huashan Hospital
Non-small Cell Lung Cancer
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
This study was designed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) in combination with pemetrexed and anlotinib for treatment of elderly patients with T790M-negative advanced…
- Trial name
- NCT06277674
- Testing
- Cadonilimab plus Pemetrexed and Anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Hepatocellular Carcinoma
TACE Combined With Penpulimab and Anlotinib for Advanced HCC
The purpose of this multicenter, dual-cohort, prospective real-world study is to explore the efficacy and safety of penpulimab and anlotinib combined with or without TACE, as well as the optimum interval of the combination of…
- Trial name
- NCT05344924
- Testing
- TACE+penpulimab+anlotinib vs. penpulimab+anlotinib
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Zhongda Hospital
Metastatic Castration-resistant Prostate Cancer (CRPC)
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
- Trial name
- NCT06249750
- Testing
- Immunotherapy, Targeted therapy, Hyperthermia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Pengyuan Liu
Cancer of Liver
Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
This is a prospective, one-arm, exploratory clinical study to observe and evaluate the efficacy and safety of Anlotinib hydrochloride capsules in patients with advanced liver cancer.
- Trial name
- ATAHC (NCT03766776)
- Testing
- Anlotinib
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Anlotinib, Durvalumab
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
- Conditions
- Anlotinib, Durvalumab, Small Cell Lung Cancer
- Trial name
- NCT04314297
- Testing
- Anlotinib In Combination With Durvalumab
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
ESCC
TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer
A Controlled Clinical Study of TC/PD-1 Inhibitors Combined With anlotinib as First-line Treatment for Advanced ESCC
- Trial name
- TC (NCT04471480)
- Testing
- TC/PD-1 inhibitor/anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Dong Wang
Carcinoma, Lung Neoplasm
Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
Investigations prospectively collected the SCLC patients who received current standard first-line treatment, the response was not progression disease(PD).
- Conditions
- Carcinoma, Lung Neoplasm, Small Cell Lung Cancer
- Trial name
- NCT03780283
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Hospital of Shijiazhuang City
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy.
- Trial name
- NCT06086197
- Testing
- Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Zhejiang Cancer Hospital
Tumor
A Phase II Study of Anlotinib in MTC Patients
Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- ALTN/MTC (NCT01874873)
- Testing
- Anlotinib
- Where
- 10 sites in China
- Volunteers
- 58 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Proteinuria
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either…
- Trial name
- NCT07358520
- Testing
- Huaier Granule, Anlotinib and Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Endometrial Carcinoma
A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma
A clinical trial to evaluate TQB2858 injection combined with Anlotinib Hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial carcinoma
- Trial name
- NCT05121363
- Testing
- TQB2858 injection, Anlotinib Hydrochloride capsules
- Where
- 2 sites in China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC
The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib is safe, effective in the treatment of limited brain metastases with Perilesional edema in non-small cell lung cancer.
- Trial name
- Rvision-001 (NCT04147728)
- Testing
- Anlotinib, Stereotactic Radiosurgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
SHR-1210, Anlotinib
SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
This study was designed to explore the clinical efficacy of SHR-1210 in combined with Anlotinib in the treatment of second- or above- line advanced or metastatic esophageal squamous cell cancer patients, in order to find a better…
- Conditions
- SHR-1210, Anlotinib, Advanced Esophageal Squamous Cell Cancer
- Trial name
- NCT04797507
- Testing
- SHR-1210 plus Anlotinib
- Volunteers
- 33 people
- Sponsor
- Peking Union Medical College Hospital
Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
This study aims to assess the efficacy and safety of a combination therapy consisting of Anlotinib, TQB2450 (a PD-L1 inhibitor), and Albumin-bound Paclitaxel regimens in patients with advanced gastric cancer (GC) or…
- Trial name
- NCT06222944
- Testing
- Anlotinib, TQB2450, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University
SCLC, Maintenance Treatment
Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell
This is a randomized, open, multicenter Phase III clinical study. A total of 136 participants are planned to be enrolled and randomly assigned to either the experimental group (platinum+etoposide → toripalimab plus anlotinib) or…
- Trial name
- SCLC (NCT06441344)
- Testing
- Toripalimab plus Anlotinib, Toripalimab
- Volunteers
- 136 people
- Sponsor
- Taizhou Hospital
Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma
- Trial name
- NCT06901622
- Testing
- Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
To explore the Objective Response Rate (ORR) of Benmelstobart combined with Anlotinib and chemotherapy as first-line treatment for large-cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine…
- Trial name
- NCT07510594
- Testing
- Benmelstobart+ Anlotinib+ Platinum + Etoposide
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital